Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK).

Full DD Report for PRTK

You must become a subscriber to view this report.


Recent News from (NASDAQ: PRTK)

The Waiting Is The Hardest Part - The Idea Guide
Many stockpickers like to take credit for unearthing an idea, and expect that once they unearth it the market will have nothing to do but come to agree with you. And that does happen sometimes - a new idea can move the market and catalyze a change in perception, or at least start the process o...
Source: SeekingAlpha
Date: September, 07 2018 14:52
Paratek Pharmaceuticals to Present at Baird's 2018 Global Healthcare Conference
BOSTON, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that it will present at Baird's 2018 Global Healthcare Conference on Wednesday, September 5 at 10:15 a.m. EDT at the InterContinental New York Barclay in New York. To access the live we...
Source: GlobeNewswire
Date: August, 29 2018 16:05
For Paratek, Only A Matter Of Time Before Stock Rises.Eventually
For a company with a new class of antibiotics on the verge of FDA approval, Paratek ( PRTK ) is down in the dumps. Earlier this month, the Antimicrobials Drug Advisory Committee voted nearly unanimously (17-1) in favor of approving Paratek’s Omadacycline for acute bacterial skin and s...
Source: SeekingAlpha
Date: August, 26 2018 18:57
Tracking Seth Klarman's Baupost Group Holdings - Q2 2018 Update
This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman’s regulatory 13F Form filed on 08/13/2018. Please visit our Tracking Seth Klarman’s Baupost Group Holdings ...
Source: SeekingAlpha
Date: August, 14 2018 05:08
Biotech Analysis Central Pharma News: Gemphire Pulls Plug, Ampio's FDA Despair, Paratek's Positive FDA Panel
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Gemphire Stops Study For treating Pediatric Patients With NASH News: This past Friday, shares of Gemphire Therapeutics ( GEMP ) fell by as much as 75...
Source: SeekingAlpha
Date: August, 13 2018 20:16
Your Daily Pharma Scoop: Strongbridge And United Reports Positive, Insmed AdCom Favored
Stocks in News: SBBP, UTHR Strongbridge Bio's Recorlev successful in late-stage study; shares up 30% premarket Discussion : Strongbridge Biopharma plc ( SBBP ) announced positive results from a Phase 3 clinical trial of RECORLEV (levoketoconazole) in patients with endogenous Cushing...
Source: SeekingAlpha
Date: August, 12 2018 03:30
FDA Advisory Committee Recommends Approval of Paratek's Omadacycline
-- Positive vote for both the skin infections and pneumonia indications -- -- FDA decision expected in early October 2018 -- BOSTON, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) today announced that the Antimicrobials Drug Advisory Committee of the...
Source: GlobeNewswire
Date: August, 08 2018 14:20
FDA Ad Com backs Paratek's omadacycline for ABSSSI
The FDA's Antimicrobial Drugs Advisory Committee has voted 17-1 backing the safety and effectiveness of Paratek Pharmaceuticals' ( PRTK ) omadacycline for the treatment of acute bacterial skin and skin structure infection ((ABSSSI)). More news on: Paratek Pharmaceuticals, Inc., Healthcare ...
Source: SeekingAlpha
Date: August, 08 2018 12:56
Paratek Drugs Worth Betting On
Investment Thesis Currently, Paratek (PRTK) is trading near an all-time low, mainly due to them missing Q2 earnings. However, Paratek should be considered a pre-revenue company, and the missed earnings should not be the main focus. In fact, this provides a greater opportunity to buy shares o...
Source: SeekingAlpha
Date: August, 08 2018 08:02
Paratek Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Omadacycline New Drug Applications for the Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections
BOSTON, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today announced that NASDAQ has halted trading of the company’...
Source: GlobeNewswire
Date: August, 08 2018 07:05

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0810.0510.07510.159.95363,404
2018-05-2111.6011.1011.7011.05322,625
2018-05-1811.4011.5011.6511.30292,601
2018-05-1711.7011.3511.7011.25794,659
2018-05-1611.9011.6512.12511.55915,149

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1466,093219,12130.1628Cover
2018-12-1337,190175,25021.2211Cover
2018-12-1237,28677,86047.8885Short
2018-12-1116,19743,62637.1269Short
2018-12-1025,42369,46536.5983Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on PRTK.


About Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK)

Logo for Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $358,451,899 - 05/11/2018
  • Issue and Outstanding: 31,443,149 - 02/28/2018

 


Recent Filings from (NASDAQ: PRTK)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: May, 09 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: April, 30 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 18 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 13 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 05 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 05 2018

 

 


Daily Technical Chart for (NASDAQ: PRTK)

Daily Technical Chart for (NASDAQ: PRTK)


Stay tuned for daily updates and more on (NASDAQ: PRTK)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: PRTK)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in PRTK is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of PRTK and does not buy, sell, or trade any shares of PRTK. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/